RecruitingEarly Phase 1NCT06346912

CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL

Studying Acute lymphoblastic leukemia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Zhejiang University
Principal Investigator
He Huang, MD
Zhejiang University
Intervention
CD19-BAFF Targeted CAR T-cells(biological)
Enrollment
20 enrolled
Eligibility
18 years · All sexes
Timeline
20242027

Study locations (1)

Collaborators

Yake Biotechnology Ltd.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06346912 on ClinicalTrials.gov

Other trials for Acute lymphoblastic leukemia

Additional recruiting or active studies for the same condition.

See all trials for Acute lymphoblastic leukemia

← Back to all trials